Country: Armenia
Language: English
Source: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում
acetylcysteine
Zambon Switzerland Ltd.
R05CB01
acetylcysteine
600mg
tablets effervescent
(10/5x2/) blisters
OTC
Registered
2015-06-18
Core Company Data Sheet_ NACo 2015.02 20 October 2015_ 1 1. NAME OF THE MEDICINAL PRODUCT Fluimucil effervescent tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One (pharmaceutical form) contains 600 mg Acetylcysteine Excipient(s): For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Effervescent tablets 4. CLINICAL PARTICULARS 4 . 1 THERAPEUTIC INDICATIONS Mucolytic agent for the treatment of respiratory system such as bronchitis, emphysema, mucoviscidosis and bronchictasia 1, 2, 3, 4, 5, 6 . 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology _Adults_ 8, 9, 10, 11 600 mg daily. Method of administration No interaction with food has been reported; there is no indication regarding product administration before or after the meals. 4 . 3 CONTRAINDICATIONS Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Children under 18 years of age. Active peptic ulcer. Phenylketonuria. Fluimucil should not be used during breastfeeding. _With caution_ - Gastric ulcer and duodenal ulcer, esophageal varices, hemoptysis, pulmonary hemorrhage, bronchial asthma, diseases of the adrenal glands, liver and / or renal failure, hypertension. Core Company Data Sheet_ NACo 2015.02 20 October 2015_ 2 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE Mucolytic agents can induce respiratory obstruction in children under 2 years of age. Due to the physiological characteristics of the airways in this age group, the ability to expectorate may be limited. Therefore mucolytic agents should not be used in children under 2 years of age (see paragraph 4.3 Contraindications). Caution is recommended when using the product in patients with peptic ulcer or history of it, especially in case of concomitant administration of other medicines with a known irritating effect on the gastric mucosa. Patients suffering from bronchial asthma must be closely monitored during therapy. Should bronchospasm occur, acetylcysteine must be stopped immediately and appropriate treatment must be initiated. The administra Read the complete document